GB2231263A - Use of neutral protease as activator for damaged neurocytes - Google Patents

Use of neutral protease as activator for damaged neurocytes Download PDF

Info

Publication number
GB2231263A
GB2231263A GB8928811A GB8928811A GB2231263A GB 2231263 A GB2231263 A GB 2231263A GB 8928811 A GB8928811 A GB 8928811A GB 8928811 A GB8928811 A GB 8928811A GB 2231263 A GB2231263 A GB 2231263A
Authority
GB
United Kingdom
Prior art keywords
activator
neurocytes
damaged
neutral protease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB8928811A
Other languages
English (en)
Other versions
GB8928811D0 (en
Inventor
Shigemi Fujisaki
Takashi Fujisaki
Junichi Yoshida
Yasuhiro Fujisaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of GB8928811D0 publication Critical patent/GB8928811D0/en
Publication of GB2231263A publication Critical patent/GB2231263A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
GB8928811A 1989-05-08 1989-12-21 Use of neutral protease as activator for damaged neurocytes Withdrawn GB2231263A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1114852A JPH02292226A (ja) 1989-05-08 1989-05-08 障害された神経細胞賦活予防治療剤

Publications (2)

Publication Number Publication Date
GB8928811D0 GB8928811D0 (en) 1990-02-28
GB2231263A true GB2231263A (en) 1990-11-14

Family

ID=14648320

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8928811A Withdrawn GB2231263A (en) 1989-05-08 1989-12-21 Use of neutral protease as activator for damaged neurocytes

Country Status (4)

Country Link
JP (1) JPH02292226A (de)
DE (2) DE3941324A1 (de)
FR (1) FR2646605B1 (de)
GB (1) GB2231263A (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009007746A2 (en) * 2007-07-06 2009-01-15 The University Of Sheffield Treatment of sensorineural hearing loss

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042012A1 (en) 2003-10-29 2005-05-12 Altus Pharmaceuticals Inc. Non-pancreatic proteases for controlling plasma cholecystokinin (cck) concentration and for treating pain
CN109295041A (zh) * 2018-10-10 2019-02-01 宁波希诺亚海洋生物科技有限公司 具有舍雷肽酶活性的多肽及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1064581A (en) * 1964-04-06 1967-04-05 Rorer Inc William H Preparations containing an antitussive and an enzyme
GB1152697A (en) * 1965-06-18 1969-05-21 Denver Chemical Mfg Company Improvements in or relating to Therapeutic Compositions
EP0057462A2 (de) * 1981-02-03 1982-08-11 Eisai Co., Ltd. Elastase enthaltende Zusammensetzung, die eine Absorbtion einer erhöhten Menge von Elastase erlaubt
GB2121685A (en) * 1982-04-30 1984-01-04 Kaken Pharma Co Ltd Protease compositions for treating blood lipids abnormality and arteriosclerosis
EP0252004A1 (de) * 1986-06-26 1988-01-07 Ciba-Geigy Ag Pharmazeutische Zusammensetzungen für die parenterale Applikation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1955844A1 (de) * 1969-11-06 1971-05-19 Blendax Werke Schneider Co Mittel zur Behandlung von Entzuendungen
US3860702A (en) * 1972-07-11 1975-01-14 Schuyler Dev Corp Anti-inflammatory compositions
JPS5826822A (ja) * 1981-08-10 1983-02-17 Kaken Pharmaceut Co Ltd 慢性腎炎治療剤
EP0133438A1 (de) * 1983-01-21 1985-02-27 Advanced Drug Technology Corporation Enzymsalbe
JPS59225122A (ja) * 1983-05-23 1984-12-18 Kaken Pharmaceut Co Ltd 悪液質治療改善剤
JPS608227A (ja) * 1983-06-28 1985-01-17 Kaken Pharmaceut Co Ltd 抗アレルギ−増強剤
US4844897A (en) * 1985-09-13 1989-07-04 Hiroshi Maeda Anti-tumor protease preparations
JPS62215533A (ja) * 1986-03-17 1987-09-22 Shigemi Fujisaki 膠原病又は関節リウマチの予防治療剤
JPS63295515A (ja) * 1987-05-26 1988-12-01 Kao Corp 腸溶性抗血液凝固・血栓溶解製剤
CH680285A5 (de) * 1987-10-02 1992-07-31 Ferag Ag

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1064581A (en) * 1964-04-06 1967-04-05 Rorer Inc William H Preparations containing an antitussive and an enzyme
GB1152697A (en) * 1965-06-18 1969-05-21 Denver Chemical Mfg Company Improvements in or relating to Therapeutic Compositions
EP0057462A2 (de) * 1981-02-03 1982-08-11 Eisai Co., Ltd. Elastase enthaltende Zusammensetzung, die eine Absorbtion einer erhöhten Menge von Elastase erlaubt
GB2121685A (en) * 1982-04-30 1984-01-04 Kaken Pharma Co Ltd Protease compositions for treating blood lipids abnormality and arteriosclerosis
EP0252004A1 (de) * 1986-06-26 1988-01-07 Ciba-Geigy Ag Pharmazeutische Zusammensetzungen für die parenterale Applikation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Martindale, The Extra Pharmacopoeia, 28th Edition,pp646-648, *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009007746A2 (en) * 2007-07-06 2009-01-15 The University Of Sheffield Treatment of sensorineural hearing loss
WO2009007746A3 (en) * 2007-07-06 2009-03-05 Univ Sheffield Treatment of sensorineural hearing loss

Also Published As

Publication number Publication date
JPH0577655B2 (de) 1993-10-27
DE3941324C2 (de) 1992-06-25
FR2646605A1 (fr) 1990-11-09
JPH02292226A (ja) 1990-12-03
FR2646605B1 (fr) 1992-08-07
DE3943649C2 (de) 1992-10-29
DE3941324A1 (de) 1990-11-15
GB8928811D0 (en) 1990-02-28

Similar Documents

Publication Publication Date Title
TW426520B (en) Pharmaceutical compositions for the treatment of macular degeneration for preventing or improving exudative and non-exudative macular degeneration
JPS62501002A (ja) 高い眼圧の防止法、緑内障の処置及び高眼圧の処置
CA2155933A1 (en) Pulmonary Administration of sCR1 and Other Complement Inhibitory Proteins
EP0348353A2 (de) Verwendung von physiologisch wirksamen Substanzen zur Herstellung von Medikamenten für Gehirn- und Nervenerkrankungen
JP2008500304A (ja) Ｄｐｐ−ｉｖ媒介症状の予防及び／又は治療用の薬剤製造のためのタンパク質加水分解物の使用
EP1480631B1 (de) Behandlung nicht-schmerzhafter blasenstörungen mit modulatoren von alpha-2-delta- calciumkanaluntereinheiten
EP0140998B1 (de) Augenpräparate
JP4278473B2 (ja) ドライアイを治療又は予防する新規医薬組成物
GB2231263A (en) Use of neutral protease as activator for damaged neurocytes
JP2000103743A (ja) チオレドキシン活性を有するファミリーに属するポリペプチド類を含有する食品、化粧品及び医薬
US5726291A (en) Amylase inhibitors
JP2009102353A (ja) ドライアイを治療又は予防する新規医薬組成物並びに加工食品
JP3183378B2 (ja) ムチン産生促進剤
HUP0003256A2 (hu) Pentozán-poliszulfát és sói alkalmazása krónikus progresszív érhegesedéssel járó betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
CA2003981C (en) Pharmaceutical compositions and use thereof in the treatment of psoriasis
Sun et al. Short peptides derived from pigment epithelium-derived factor attenuate retinal ischemia reperfusion injury through inhibition of apoptosis and inflammatory response in rats
AU2020298782A1 (en) Combination therapy methods, compositions and kits
US20220257536A1 (en) Ketamine and ketamine/nap for treatment of adnp syndrome and related neurological conditions
WO2017088177A1 (zh) 贻贝粘蛋白产品及其预防和抑制神经炎症的应用
JP2547325B2 (ja) アレルギ−性疾患治療用外用剤
JP2982078B2 (ja) イヌ上皮細胞成長因子、該イヌ上皮細胞成長因子を有効成分とする抗炎症剤又は化粧料、及び該イヌ上皮細胞成長因子ｃＥＧＦの製造方法
JPH01290631A (ja) 血管内皮細胞増殖抑制剤
EP0679659A1 (de) Inhibitor peptid spezifisch für cathepsin-l
JP2890170B2 (ja) メタロエンドペプチダーゼｆ及びそれを有効成分とする薬剤
JPH04971B2 (de)

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)